Cost of Revenue Comparison: Insmed Incorporated vs Walgreens Boots Alliance, Inc.

Cost of Revenue: A Tale of Two Companies

In the ever-evolving landscape of corporate finance, understanding cost structures is crucial. This analysis juxtaposes the cost of revenue for Insmed Incorporated and Walgreens Boots Alliance, Inc. from 2014 to 2023. Over this period, Walgreens consistently reported a cost of revenue that dwarfed Insmed's, with figures often exceeding Insmed's by over 1,000 times. For instance, in 2023, Walgreens' cost of revenue was approximately $112 billion, while Insmed's was around $66 million.

Key Insights

• Growth Trajectory: Insmed's cost of revenue grew by nearly 1,900% from 2015 to 2023, reflecting its expanding operations.
• Walgreens' Stability: Walgreens maintained a steady increase, with a notable 11% rise from 2022 to 2023.
• Missing Data: The absence of Insmed's 2024 data suggests potential reporting delays or strategic shifts.
  This comparison highlights the stark differences in scale and operational focus between a pharmaceutical company and a retail giant.